The "decompressing stoma - neoadjuvant Folfox chemotherapy - colectomy" strategy for non-metastatic obstructive colon cancer: A French retrospective multi-institutional case series.
Melinda Bajul, Hélène Meillat, Benjamin Fernandez, Niki Christou, Claire Gallois, Antoine Cazelles, Camélia Labiad, Julien Taieb, Gilles Manceau, Mehdi Karoui
Clin Res Hepatol Gastroenterol 50(4) 102787
摘要
摘要
PURPOSE: Obstructive colon cancer (OCC) carries a poor prognosis, and the high morbidity of emergency resection often delays or precludes adjuvant chemotherapy. This study aimed to assess the feasibility and postoperative outcomes of a multimodal strategy combining decompression by diverting stoma, neoadjuvant chemotherapy (NAC), and elective colectomy in non-metastatic OCC. METHODS: Between 2016 and 2023, 41 patients with non-metastatic OCC were managed in four French centers using the sequence "decompressing stoma - systemic FOLFOX NAC - elective colectomy." RESULTS: Eight patients with right-sided OCC underwent ileostomy. The median number of NAC cycles was 4 (range, 1-12), with grade ≥3 toxicity observed in 15%. One MSI patient switched to immunotherapy after one cycle. One patient experienced tumor progression during NAC and did not undergo surgery. Elective colectomy (n = 40) was performed by minimally invasive surgery in 73% of cases, with no mortality and 13% grade ≥3 morbidity. One patient had an R1 resection, and 2 (5%) achieved a pathological complete response (ypT0N0). Adjuvant chemotherapy was delivered in 78% of cases. After a median follow-up of 24.9 months (range, 6.4-78.8), 3-year overall and disease-free survival rates were 88% and 80%, respectively. CONCLUSIONS: The sequence "decompressing stoma - FOLFOX NAC - colectomy" is safe, feasible, and may offer oncological benefit in non-metastatic OCC. Validation in a randomized phase III trial is warranted. The COnCERTO trial (ClinicalTrials.gov NCT06107920) is currently ongoing in France.
KM 提取结果
0 个 Figure · 0 个 KM 面板